S. Tshimanga, A. Fouad, K. Fakiri, N. Rada, G. Draiss, N. Soraa, Brahim Admou, M. Bouskraoui
{"title":"儿童HIV感染所致继发性支气管扩张","authors":"S. Tshimanga, A. Fouad, K. Fakiri, N. Rada, G. Draiss, N. Soraa, Brahim Admou, M. Bouskraoui","doi":"10.30654/mjhiv.10021","DOIUrl":null,"url":null,"abstract":"Introduction: Bronchiectasis is defined as a permanent and irreversible dilatation of the bronchial airways. Its association with HIV infection in the pediatric population is not widely reported in the literature. The objective was to analyze the epidemiological, clinical, etiological, therapeutic and evolutionary profile of secondary bronchiectasis due to HIV infection children. We retrospectively studied 6 cases of secondary bronchiectasis due to HIV infection children collected at the pediatric ward B of the Mohammed VI University Hospital in Marrakech over a period of 7 years from January 2012 to December 2018. There was no difference between the two sexes, an average age of 61.3 months. All 6 cases had recurrent pneumonia preceding the diagnosis of bronchiectasis; in the 5 cases with CD4 T cell counts 4 had a count less than 100 cells/mm3. The entire chest CT scan enabled us to make the diagnosis of bronchiectasis in all the patients. The management of all our patients consisted of a good hydration, a postural drainage physiotherapy, an appropriate antibiotherapy based on the germ in question, and finally an antiretroviral therapy. The clinicovirological outcome was satisfactory for all the cases, all cases had an undetectable viral load between 6-12 months of specific treatment, an improved CD4 T cell count, and no exacerbation of bronchial dilation within one year of initiation of antiretroviral therapy.","PeriodicalId":153644,"journal":{"name":"Mathews Journal of HIV/AIDS","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Secondary Bronchiectasis due to HIV Infection in Children\",\"authors\":\"S. Tshimanga, A. Fouad, K. Fakiri, N. Rada, G. Draiss, N. Soraa, Brahim Admou, M. Bouskraoui\",\"doi\":\"10.30654/mjhiv.10021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Bronchiectasis is defined as a permanent and irreversible dilatation of the bronchial airways. Its association with HIV infection in the pediatric population is not widely reported in the literature. The objective was to analyze the epidemiological, clinical, etiological, therapeutic and evolutionary profile of secondary bronchiectasis due to HIV infection children. We retrospectively studied 6 cases of secondary bronchiectasis due to HIV infection children collected at the pediatric ward B of the Mohammed VI University Hospital in Marrakech over a period of 7 years from January 2012 to December 2018. There was no difference between the two sexes, an average age of 61.3 months. All 6 cases had recurrent pneumonia preceding the diagnosis of bronchiectasis; in the 5 cases with CD4 T cell counts 4 had a count less than 100 cells/mm3. The entire chest CT scan enabled us to make the diagnosis of bronchiectasis in all the patients. The management of all our patients consisted of a good hydration, a postural drainage physiotherapy, an appropriate antibiotherapy based on the germ in question, and finally an antiretroviral therapy. The clinicovirological outcome was satisfactory for all the cases, all cases had an undetectable viral load between 6-12 months of specific treatment, an improved CD4 T cell count, and no exacerbation of bronchial dilation within one year of initiation of antiretroviral therapy.\",\"PeriodicalId\":153644,\"journal\":{\"name\":\"Mathews Journal of HIV/AIDS\",\"volume\":\"11 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mathews Journal of HIV/AIDS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30654/mjhiv.10021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mathews Journal of HIV/AIDS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30654/mjhiv.10021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Secondary Bronchiectasis due to HIV Infection in Children
Introduction: Bronchiectasis is defined as a permanent and irreversible dilatation of the bronchial airways. Its association with HIV infection in the pediatric population is not widely reported in the literature. The objective was to analyze the epidemiological, clinical, etiological, therapeutic and evolutionary profile of secondary bronchiectasis due to HIV infection children. We retrospectively studied 6 cases of secondary bronchiectasis due to HIV infection children collected at the pediatric ward B of the Mohammed VI University Hospital in Marrakech over a period of 7 years from January 2012 to December 2018. There was no difference between the two sexes, an average age of 61.3 months. All 6 cases had recurrent pneumonia preceding the diagnosis of bronchiectasis; in the 5 cases with CD4 T cell counts 4 had a count less than 100 cells/mm3. The entire chest CT scan enabled us to make the diagnosis of bronchiectasis in all the patients. The management of all our patients consisted of a good hydration, a postural drainage physiotherapy, an appropriate antibiotherapy based on the germ in question, and finally an antiretroviral therapy. The clinicovirological outcome was satisfactory for all the cases, all cases had an undetectable viral load between 6-12 months of specific treatment, an improved CD4 T cell count, and no exacerbation of bronchial dilation within one year of initiation of antiretroviral therapy.